NBL1 Antibody

What is NBL1 and why is it significant in research?

NBL1, also known as DAN, DAND1, or Zinc finger protein DAN, functions as a tumor suppressor gene, particularly in neuroblastoma. This protein plays a crucial role in preventing cells from entering the final stage (G1/S) of the transformation process, making it an important regulatory protein in cell cycle control . NBL1 has been identified as having growth inhibitory effects in multiple cell types, particularly in the context of cancer research and vascular biology. Recent studies have demonstrated that NBL1 can effectively inhibit platelet-derived growth factor (PDGF)-BB-induced cell proliferation, suggesting its potential role in regulating abnormal cell growth in pathological conditions .

What types of NBL1 antibodies are available for research applications?

There are several types of NBL1 antibodies available for research, each with specific characteristics:

• Polyclonal antibodies: These are typically rabbit-derived and recognize multiple epitopes of the NBL1 protein. For example, the rabbit polyclonal antibody (A46805) is designed for immunohistochemistry (IHC) applications with human samples and has a concentration of 2.1 mg/ml .

• Monoclonal antibodies: Such as the rabbit recombinant monoclonal antibody [EPR12397], which offers higher specificity and consistency between batches. This antibody is suitable for multiple applications including immunocytochemistry/immunofluorescence (ICC/IF), western blotting (WB), and flow cytometry (intracellular) .

The choice between polyclonal and monoclonal antibodies depends on the specific experimental requirements, with polyclonal antibodies offering broader epitope recognition and monoclonal antibodies providing higher specificity for particular epitopes.

What are the validated applications for NBL1 antibodies?

NBL1 antibodies have been validated for several experimental techniques:

When selecting an NBL1 antibody, researchers should consider which applications they intend to use and whether the antibody has been validated for those specific techniques. For example, if immunohistochemical analysis of human tissue samples is planned, the rabbit polyclonal antibody (A46805) would be an appropriate choice as it has been specifically validated for this application .

How should NBL1 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of NBL1 antibodies is critical for maintaining their specificity and activity. Based on manufacturer recommendations, most NBL1 antibodies should be stored at -20°C . The antibodies are typically formulated in a stabilizing solution containing PBS, glycerol, and sodium azide (NaN3) as a preservative. The specific formulation for the rabbit polyclonal antibody (A46805) is rabbit IgG in pH 7.3 PBS with 0.05% NaN3 and 50% glycerol .

For optimal results, researchers should:

• Avoid repeated freeze-thaw cycles by aliquoting the antibody upon receipt

• Thaw antibodies completely before use and mix gently to ensure homogeneity

• Return antibodies to -20°C immediately after use

• Follow manufacturer's recommendations for dilution factors in specific applications

How can NBL1 antibodies be used to investigate cell cycle regulation mechanisms?

NBL1 has been identified as an important regulator of cell cycle progression, specifically in preventing cells from entering the G1/S phase. Researchers can use NBL1 antibodies to investigate this mechanism through several advanced approaches:

• Co-immunoprecipitation (co-IP) experiments to study the interaction between NBL1 and cell cycle regulators such as cyclin D1-CDK4 complex. Studies have shown that NBL1 reduces cyclin D1-CDK4 complex formation induced by PDGF-BB in human PASMCs .

• Western blot analysis using phospho-specific antibodies to examine the effect of NBL1 on the phosphorylation status of cell cycle inhibitors like p27. Research has demonstrated that NBL1 decreases the phosphorylation of p27, which is associated with increased p27 protein stability .

• Chromatin immunoprecipitation (ChIP) assays to investigate whether NBL1 regulates the expression of cell cycle genes at the transcriptional level.

The experimental protocol should include appropriate controls such as siRNA-mediated knockdown of NBL1 to validate the specificity of observed effects. In previous studies, p27 knockdown was shown to block the growth arrest induced by NBL1, confirming the functional relationship between these proteins .

What role does NBL1 play in PDGF-BB signaling in pulmonary arterial smooth muscle cells?

NBL1 has been shown to have a dose-dependent inhibitory effect on PDGF-BB-induced proliferation of human pulmonary arterial smooth muscle cells (PASMCs). This makes it a potential therapeutic target for pulmonary arterial hypertension (PAH), a condition characterized by excessive PASMC proliferation and vascular remodeling .

Researchers studying this pathway can use NBL1 antibodies to:

• Detect changes in NBL1 expression levels in normal versus PAH models using western blotting or immunohistochemistry.

• Investigate the signaling cascade by which NBL1 inhibits PDGF-BB-induced PASMC proliferation. Studies have shown that NBL1 blocks the PDGFRβ-p38 MAPK signaling pathway .

• Examine the downstream effects of NBL1 on cell cycle regulators, including:

  • Decreased expression of cyclin D1 and CDK4

  • Reduced formation of cyclin D1-CDK4 complexes

  • Decreased phosphorylation of p27, leading to increased p27 protein levels

The experimental approach should include dose-response studies (with NBL1 concentrations ranging from 0.25 to 1 μM) and time-course experiments to fully characterize the inhibitory effect .

What are the optimal protocols for using NBL1 antibodies in immunohistochemistry?

For successful immunohistochemical detection of NBL1 in tissue samples, researchers should follow these methodological steps:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded tissue sections (4-6 μm thickness)

  • Perform antigen retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Block endogenous peroxidase activity with 3% hydrogen peroxide

• Antibody incubation:

  • Use the rabbit polyclonal anti-NBL1 antibody (A46805) at a dilution of 1/50

  • Incubate at 4°C overnight or at room temperature for 1-2 hours

• Detection system:

  • Apply appropriate secondary antibodies such as:

    • Goat Anti-Rabbit IgG H&L Antibody (AP) (A294874)

    • Goat Anti-Rabbit IgG H&L Antibody (Biotin) (A294795)

    • Goat Anti-Rabbit IgG H&L Antibody (FITC) (A294887)

    • Goat Anti-Rabbit IgG H&L Antibody (HRP) (A294888)

  • Develop the signal using DAB substrate for HRP or appropriate substrates for other enzymes

  • Counterstain with hematoxylin, dehydrate, and mount

The protocol has been validated for human thyroid cancer tissue, demonstrating specific staining of NBL1 protein . When performing these experiments, it is essential to include positive and negative controls to validate antibody specificity.

How can researchers validate the specificity of NBL1 antibodies in their experimental systems?

Validating antibody specificity is crucial for ensuring reliable experimental results. For NBL1 antibodies, researchers should consider the following validation approaches:

• Genetic validation:

  • Use NBL1 knockout or knockdown models (siRNA or CRISPR) as negative controls

  • Overexpress NBL1 in cells with low endogenous expression as positive controls

  • Compare immunostaining patterns or western blot bands between wild-type and knockout/knockdown samples

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide or recombinant NBL1 protein

  • Compare staining between blocked and unblocked antibody samples

  • Specific signals should be significantly reduced or eliminated when the antibody is blocked

• Multiple antibody validation:

  • Compare results using different antibodies targeting distinct epitopes of NBL1

  • Consistent results across different antibodies increase confidence in specificity

• Cross-reactivity assessment:

  • Test the antibody on samples from different species to confirm predicted reactivity

  • Verify that the antibody does not detect closely related proteins by western blotting

For NBL1 antibodies specifically, they should detect a protein at the expected molecular weight (approximately 20-23 kDa) in western blot applications and show the expected cellular localization pattern in immunostaining experiments.

What are the considerations for using NBL1 antibodies in studying vascular pathologies?

NBL1 has demonstrated promising potential as a therapeutic target for pulmonary arterial hypertension due to its ability to inhibit PASMC proliferation. When using NBL1 antibodies to study vascular pathologies, researchers should consider these methodological approaches:

• Disease model selection:

  • Animal models of PAH (e.g., monocrotaline-induced or hypoxia-induced)

  • Human patient samples from individuals with PAH versus healthy controls

  • Primary cell culture models of human PASMCs treated with disease-relevant stimuli like PDGF-BB

• Functional assays to assess NBL1 effects:

  • Cell proliferation assays (MTS assay, EdU incorporation)

  • Analysis of PCNA expression by western blotting

  • Cell cycle analysis by flow cytometry

  • DNA synthesis measurements

• Mechanistic investigations:

  • Examination of signaling pathway components (PDGFRβ-p38MAPK)

  • Analysis of cell cycle regulators (cyclin D1, CDK4, p27)

  • Phosphorylation status of p27 and its correlation with NBL1 expression

Research has shown that NBL1 doses between 0.5 and 1 μM inhibit PDGF-BB-induced proliferation of human PASMCs, with 0.5 μM being the lowest effective dose . This dose-dependent effect should be considered when designing experiments to study NBL1's role in vascular pathologies.

What are common issues encountered with NBL1 antibodies and how can they be resolved?

When working with NBL1 antibodies, researchers may encounter several technical challenges. Here are common issues and their solutions:

• High background in immunostaining:

  • Increase blocking time and concentration (5% BSA or normal serum)

  • Optimize antibody dilution (start with manufacturer's recommendation and adjust)

  • Reduce secondary antibody concentration

  • Include additional washing steps with agitation

• Weak or no signal in western blotting:

  • Ensure adequate protein loading (20-50 μg total protein)

  • Optimize transfer conditions for proteins in NBL1's molecular weight range

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection systems (enhanced chemiluminescence)

  • Verify that sample preparation preserves NBL1 protein integrity

• Non-specific bands in western blotting:

  • Increase blocking stringency

  • Optimize antibody dilution

  • Use gradient gels to better resolve proteins of similar molecular weights

  • Consider using more specific monoclonal antibodies

• Variable results between experiments:

  • Standardize protocols, including fixation methods and antibody incubation times

  • Use consistent lot numbers of antibodies when possible

  • Include positive and negative controls in each experiment

  • Prepare master mixes of reagents to minimize pipetting errors

How do different fixation methods affect NBL1 antibody performance in immunohistochemistry?

The choice of fixation method can significantly impact antibody binding and epitope accessibility for NBL1 detection:

• Formalin fixation (most common):

  • Provides good morphological preservation

  • May mask epitopes, requiring appropriate antigen retrieval

  • For NBL1 detection, heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective

• Paraformaldehyde fixation:

  • Milder than formalin, potentially preserving more epitopes

  • Suitable for frozen sections and cell preparations

  • May require shorter fixation times (10-20 minutes)

• Alcohol-based fixatives (ethanol, methanol):

  • Preserve some epitopes better than aldehyde fixatives

  • May extract lipids, altering membrane protein distribution

  • Often used for intracellular proteins

• Acetone fixation:

  • Minimal cross-linking, good for preserving protein antigenicity

  • Poor morphological preservation

  • Quick fixation (5-10 minutes at -20°C)

The rabbit polyclonal NBL1 antibody (A46805) has been validated for use with paraffin-embedded tissue sections following formalin fixation . When using different fixation methods, researchers should perform validation experiments to determine optimal conditions for their specific application.

What emerging technologies can enhance NBL1 antibody applications?

Several cutting-edge technologies can expand the utility of NBL1 antibodies in research:

• Proximity ligation assay (PLA):

  • Enables visualization of protein-protein interactions at the single-molecule level

  • Could be used to study interactions between NBL1 and its binding partners in situ

  • Particularly useful for investigating NBL1's interaction with cell cycle regulators like CDK4

• Mass cytometry (CyTOF):

  • Allows simultaneous detection of multiple proteins using metal-tagged antibodies

  • Enables comprehensive analysis of NBL1 expression in relation to other signaling molecules

  • The conjugation-ready format of NBL1 antibodies makes them suitable for metal isotope labeling

• Multiplex imaging:

  • Techniques like multiplexed immunofluorescence or imaging mass cytometry

  • Enables spatial analysis of NBL1 expression in complex tissues

  • NBL1 antibodies in carrier-free formats are suitable for these applications

• CRISPR-based functional genomics:

  • Combine CRISPR gene editing with antibody-based detection

  • Create knock-in tags for endogenous NBL1 protein visualization

  • Study the effects of NBL1 variants on protein localization and function

What are potential therapeutic applications of NBL1 research using antibody-based techniques?

Research using NBL1 antibodies points to several promising therapeutic directions:

• Pulmonary arterial hypertension therapy:

  • NBL1 inhibits PDGF-BB-induced PASMC proliferation, a key process in PAH pathogenesis

  • Antibody-based screening could identify compounds that upregulate or mimic NBL1 function

  • Therapeutic potential through blockade of PDGFRβ-p38MAPK signaling

• Cancer therapeutics:

  • As a tumor suppressor gene for neuroblastoma, NBL1 restoration could inhibit tumor growth

  • Antibodies can be used to screen for compounds that induce NBL1 expression in cancer cells

  • Monitor NBL1 expression as a biomarker for treatment response

• Diagnostic applications:

  • Develop immunohistochemical panels including NBL1 for cancer diagnosis

  • Potential prognostic marker for certain cancer types

  • Antibody-based tissue microarray analysis to correlate NBL1 expression with clinical outcomes

• Drug development:

  • Screen for compounds that modulate NBL1's interaction with the cell cycle machinery

  • Identify small molecules that mimic NBL1's inhibitory effect on PDGF signaling

  • Develop therapeutic antibodies that can enhance NBL1 function

The research on NBL1's role in inhibiting PASMC proliferation via the PDGFRβ-p38MAPK pathway provides a strong foundation for developing targeted therapies for PAH, a condition with limited treatment options .